Your browser is no longer supported. Please, upgrade your browser.
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own15.34% Shs Outstand14.31M Perf Week-5.45%
Market Cap35.79M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float12.12M Perf Month-1.62%
Income-16.90M PEG- EPS next Q-0.28 Inst Own29.70% Short Float1.22% Perf Quarter5.65%
Sales4.00M P/S8.95 EPS this Y29.40% Inst Trans- Short Ratio0.33 Perf Half Y-12.27%
Book/sh0.54 P/B4.50 EPS next Y-48.30% ROA-59.10% Target Price- Perf Year-15.03%
Cash/sh1.50 P/C1.62 EPS next 5Y- ROE-183.20% 52W Range2.28 - 5.39 Perf YTD-7.25%
Dividend- P/FCF- EPS past 5Y37.30% ROI- 52W High-54.92% Beta1.24
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low6.58% ATR0.14
Employees20 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)43.43 Volatility5.77% 4.96%
OptionableYes Debt/Eq0.00 EPS Q/Q59.50% Profit Margin- Rel Volume0.25 Prev Close2.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume444.29K Price2.43
Recom2.50 SMA20-4.68% SMA50-4.84% SMA200-16.50% Volume110,534 Change-2.80%
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Oct-09-21 08:09AM  
Oct-07-21 10:58AM  
08:44AM  
08:30AM  
Oct-06-21 12:08PM  
08:30AM  
07:21AM  
07:12AM  
Oct-01-21 08:04PM  
Sep-06-21 08:00AM  
Aug-30-21 08:30AM  
Aug-10-21 06:45PM  
04:05PM  
Aug-09-21 08:30AM  
01:30AM  
Jul-08-21 11:20AM  
Jun-23-21 09:35AM  
Jun-22-21 06:46AM  
Jun-13-21 02:11PM  
Jun-10-21 08:30AM  
Jun-09-21 12:00PM  
May-25-21 08:30AM  
May-17-21 04:01PM  
Mar-30-21 01:23AM  
Mar-29-21 08:30AM  
Mar-25-21 04:05PM  
Mar-22-21 08:30AM  
Mar-15-21 08:37AM  
Mar-01-21 04:05PM  
08:30AM  
Feb-11-21 08:30AM  
Jan-25-21 08:35AM  
Dec-22-20 08:30AM  
Dec-17-20 08:30AM  
Nov-10-20 04:05PM  
Oct-15-20 09:30AM  
Oct-02-20 02:37PM  
Oct-01-20 07:04AM  
Sep-28-20 03:30PM  
Aug-31-20 05:00PM  
Aug-25-20 09:00AM  
Aug-13-20 04:01PM  
Aug-05-20 09:00AM  
Jul-28-20 11:09AM  
Jul-27-20 07:29PM  
Jul-09-20 03:55PM  
03:43PM  
Jul-08-20 04:01PM  
Jun-24-20 01:53PM  
May-29-20 12:44PM  
May-21-20 08:30AM  
May-14-20 04:01PM  
May-11-20 04:05PM  
Apr-30-20 04:01PM  
Mar-18-20 04:05PM  
04:05PM  
Feb-26-20 03:00AM  
Feb-25-20 03:00AM  
Feb-24-20 04:05PM  
Jan-28-20 06:16PM  
Jan-05-20 07:00AM  
Dec-23-19 03:59PM  
Dec-17-19 07:56AM  
Dec-16-19 04:05PM  
Dec-05-19 12:50PM  
Nov-13-19 04:05PM  
Oct-28-19 04:01PM  
Oct-07-19 07:05AM  
Sep-11-19 08:00PM  
Aug-30-19 03:00PM  
02:30PM  
01:02PM  
10:04AM  
08:59AM  
Aug-29-19 10:00PM  
03:18PM  
12:27PM  
12:23PM  
Aug-28-19 09:34PM  
06:46PM  
01:00PM  
10:02AM  
Aug-27-19 10:00AM  
08:30AM  
06:35AM  
Aug-26-19 08:00PM  
07:33PM  
06:14PM  
Aug-25-19 10:28AM  
Aug-24-19 06:55AM  
Aug-23-19 08:00PM  
08:00PM  
06:06PM  
05:37PM  
03:00PM  
10:46AM  
Aug-22-19 08:45PM  
01:00PM  
06:30AM  
Aug-21-19 09:44PM  
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts.